Image-Guided Brachytherapy for Gynecologic Cancers
Trial Summary
What is the purpose of this trial?
This research is being done to evaluate multimodality imaging, including magnetic resonance imaging-guided therapy (MRT), as a possible treatment for gynecologic cancers. The therapy takes place in the Department of Radiation Oncology at the Johns Hopkins SKCCC. The purpose of this study is to investigate the ability of MRI to successfully guide the placement of the brachytherapy applicator necessary to treat participants' gynecologic cancer. The Investigators want to see if the use of MRI will do a better job of assessing the tumor at the time of brachytherapy than the routinely used CT scan. The Investigators also want to determine if the use of MRI will enable doctors to reduce the radiation dose received by the body during the process of treating the tumor.
Do I need to stop my current medications for this trial?
The trial information does not specify if you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.
What data supports the effectiveness of the treatment Image-Guided Brachytherapy for Gynecologic Cancers?
Is image-guided brachytherapy (IGBT) safe for humans?
Research on image-guided brachytherapy (IGBT) for cervical cancer shows that it is generally safe, with studies reporting on its use and associated toxicity profiles. These studies focus on managing side effects and improving treatment delivery, indicating that safety is a key consideration in its application.15678
How is Image-Guided Brachytherapy different from other treatments for gynecologic cancers?
Image-Guided Brachytherapy (IGBT) is unique because it uses advanced imaging techniques like MRI and CT scans to precisely target cancerous tissues in gynecologic cancers, allowing for more accurate and effective radiation delivery compared to traditional methods. This approach can improve treatment outcomes and reduce damage to surrounding healthy tissues.148910
Research Team
Akila Viswanathan, M.D.
Principal Investigator
Johns Hopkins Department of Radiation Oncology
Eligibility Criteria
This trial is for adults over 18 with various gynecologic cancers (vulvar, vaginal, bladder, uterine, cervical) who are eligible for internal radiation therapy. They must have a life expectancy of more than 6 months and be physically able to participate (ECOG <2). Prior treatments like radiation or chemotherapy are allowed. Exclusions include severe illnesses that could affect study participation or having metal in the head/eyes.Inclusion Criteria
Exclusion Criteria
Trial Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants undergo MRI-guided brachytherapy to treat gynecologic cancer
Follow-up
Participants are monitored for safety and effectiveness after treatment
Long-term follow-up
Participants are monitored for long-term outcomes such as survival and local failure rates
Treatment Details
Interventions
- Image-Guided Brachytherapy (Brachytherapy)
Image-Guided Brachytherapy is already approved in Canada for the following indications:
- Cervical cancer
- Endometrial cancer
- Vaginal cancer
Find a Clinic Near You
Who Is Running the Clinical Trial?
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Lead Sponsor
Dr. William G. Nelson
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Director since 1992
MD, PhD
Dr. Elizabeth Jaffee
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Chief Medical Officer since 2023
MD
National Cancer Institute (NCI)
Collaborator
Dr. Douglas R. Lowy
National Cancer Institute (NCI)
Chief Executive Officer since 2023
MD from New York University School of Medicine
Dr. Monica Bertagnolli
National Cancer Institute (NCI)
Chief Medical Officer since 2022
MD from Harvard Medical School